Twist Bioscience (TWST) CFO sells shares for tax withholding in Form 4 filing

Rhea-AI Filing Summary

Twist Bioscience Corp's Chief Financial Officer, Adam Laponis, reported an automatic sale of common stock to cover taxes related to equity compensation. On January 9, 2026, he sold 2,738 shares of common stock at a price of $35.261 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and were executed as mandatory "sell to cover" transactions rather than discretionary trades. After this sale, Laponis directly beneficially owned 140,031 shares of Twist Bioscience common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		S		2,738(1)	D	$35.261	140,031	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Twist Bioscience (TWST) report for its CFO?

Twist Bioscience reported that its Chief Financial Officer, Adam Laponis, sold 2,738 shares of common stock on January 9, 2026, in a transaction disclosed on Form 4.

At what price were the Twist Bioscience (TWST) shares sold by the CFO?

The 2,738 shares of Twist Bioscience common stock were sold at a price of $35.261 per share.

Why did the Twist Bioscience CFO sell 2,738 shares according to the Form 4?

The Form 4 states that the 2,738 shares were sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units, under a mandated "sell to cover" election in the company’s equity incentive plans.

Were the Twist Bioscience CFO’s reported share sales discretionary trades?

No. The filing explains that the sales were mandated by the issuer’s election to fund tax withholding via a "sell to cover" transaction and do not represent discretionary trades by the CFO.

How many Twist Bioscience (TWST) shares does the CFO own after the reported transaction?

After the reported sale, Chief Financial Officer Adam Laponis directly beneficially owned 140,031 shares of Twist Bioscience common stock.

What is the reporting person’s role at Twist Bioscience in this Form 4?

The reporting person, Adam Laponis, is identified as an officer of Twist Bioscience, serving as the company’s Chief Financial Officer.